Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of RSVPreF3 OA vaccine efficacy and annual revaccination in adults aged 60 years and older
2020-000753-28Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing RSVPreF3 OA vaccine with Placebo (2 arms). Primary endpoint: First episode of RT-PCR confirmed RSV A and/or B associated lower respiratory tract disease during the first season. Started Jan 2021; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2020-000753-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000753-28.